{"id":"W4295445025","doi":"10.1111/cts.13387","title":"Manufacturing‐dependent change in biological activity of the <scp>TLR4</scp> agonist <scp>GSK1795091</scp> and implications for lipid A analog development","year":2022,"lang":"en","type":"article","venue":"Clinical and Translational Science","topic":"Immune Response and Inflammation","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Chugai Pharmaceutical; Sanofi Genzyme; Merck Sharp and Dohme; EMD Serono; Genentech; MacroGenics; Silverback Therapeutics; Principia Biopharma; Puma Biotechnology; F-star Therapeutics; Aminex Therapeutics; BeiGene; Mirati Therapeutics; Jounce Therapeutics; Wellcome Trust; Array BioPharma; Five Prime Therapeutics; Conquer Cancer Foundation; Taiho Pharmaceutical; National Institutes of Health; Regeneron Pharmaceuticals; BioMarin Pharmaceutical; Daiichi Sankyo Europe; National Cancer Institute; Intuitive Surgical; Gilead Sciences; Bristol-Myers Squibb; ImmunoMedics; Adenoid Cystic Carcinoma Research Foundation; Eli Lilly and Company; American Society of Clinical Oncology; GlaxoSmithKline; Gateway for Cancer Research; Exelixis; Sanofi; Abbott Laboratories; Incyte; Pfizer; Amgen","keywords":"Medicine; Pharmacodynamics; Agonist; Chills; Adverse effect; Cytokine; Pharmacology; Pharmacokinetics; Nausea; TLR4; Clinical endpoint; Immunotherapy; Clinical trial; Immune system; Internal medicine; Immunology; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001640596,0.00009839921,0.0001875635,0.00008615854,0.0008013803,0.00001591246,0.0002637715,0.00009590783,0.00001166204],"category_scores_gemma":[0.0003060659,0.00007008901,0.00006564514,0.000201522,0.0009449039,0.0001264241,0.0001579147,0.0002467204,0.000001815145],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001661604,"about_ca_system_score_gemma":0.0001849717,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002447188,"about_ca_topic_score_gemma":0.00004021655,"domain_scores_codex":[0.9987545,0.000210049,0.0003860154,0.0003368662,0.00007427249,0.0002383232],"domain_scores_gemma":[0.9982698,0.001382455,0.0001446627,0.0001311148,0.00004249349,0.0000294877],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001350082,0.0008208503,0.6161065,0.00004835949,0.00008775037,8.239389e-7,0.003678854,0.00004130432,0.2319478,0.01088353,0.0001581232,0.1360912],"study_design_scores_gemma":[0.0006683379,0.000114391,0.9532307,0.000007053027,0.000008544938,0.00001321345,0.00006991265,0.00003081706,0.02170998,0.001167247,0.02295589,0.00002388244],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973732,0.0004395278,0.0001806353,0.001125128,0.000204154,0.000451717,0.000047498,0.0000101983,0.0001679813],"genre_scores_gemma":[0.9992763,0.00009694818,0.0001292903,0.0001384377,0.00002179807,0.000148723,0.00002822579,0.000003105638,0.0001571561],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3371243,"threshold_uncertainty_score":0.616365,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07507872474596153,"score_gpt":0.3287074352560683,"score_spread":0.2536287105101068,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}